Trials / Completed
CompletedNCT00408239
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement: A Randomized, Enoxaparin-controlled, Open Label, Dose-escalation Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 367 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety and tolerability of escalating oral doses of YM150 in patients undergoing elective primary total knee replacement surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM150 | Oral |
| DRUG | enoxaparin | Sub cutaneous |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2006-12-06
- Last updated
- 2011-12-19
Locations
19 sites across 8 countries: Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand
Source: ClinicalTrials.gov record NCT00408239. Inclusion in this directory is not an endorsement.